Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 2/20 | 0.44 |
| ▸ | FGF2 | P09038 | 2/20 | 0.44 |
| ▸ | VEGFA | P15692 | 2/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.44 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.40 |
| ▸ | GRK2 | P25098 | 1/20 | 0.40 |
| ▸ | GJB2 | P29033 | 2/20 | 0.40 |
| ▸ | GJA1 | P17302 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778308 | 0.85 | LGALS3 (0.44) | FGF1FGF2VEGFAHPSELGALS9 | |
| SCHEMBL7769023 | 0.85 | CA1 (0.41) | FGF1FGF2VEGFAHPSECA1 | |
| SCHEMBL7640784 | 0.84 | LMNA (0.46) | FGF1FGF2VEGFAHPSELGALS9 | |
| SCHEMBL7640793 | 0.84 | LMNA (0.46) | FGF1FGF2VEGFAHPSELGALS9 | |
| SCHEMBL28316892 | 0.83 | FGF1 (0.52) | FGF1FGF2VEGFAHPSECA1 | |
| SCHEMBL18819802 | 0.83 | CA9 (0.48) | FGF1CA1CA2CA9 | |
| SCHEMBL2785750 | 0.83 | CA9 (0.48) | FGF1CA1CA2CA9 | |
| SCHEMBL14906758 | 0.83 | CA9 (0.48) | FGF1CA1CA2CA9 | |
| SCHEMBL17179731 | 0.83 | CA9 (0.48) | FGF1CA1CA2CA9 | |
| SCHEMBL18517532 | 0.83 | CA9 (0.48) | FGF1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109735-A1 | SALACINOL AND PONKORANOL HOMOLOGUES, DERIVATIVES THEREOF, AND METHODS OF SYNTHESIZING SAME | SIMON FRASER UNIVERSITY (CA) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109735-A1 | SALACINOL AND PONKORANOL HOMOLOGUES, DERIVATIVES THEREOF, AND METHODS OF SYNTHESIZING SAME | GBA3, SI, GANAB | FGF1 3416/4885FGF2 3552/4885VEGFA 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.